- Home
- CMMB vs APM Comparison
CMMB vs APM Comparison
Compare CMMB & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- APM
- Stock Information
- Founded
- CMMB 2004
- APM 2010
- Country
- CMMB Israel
- APM United Kingdom
- Employees
- CMMB N/A
- APM N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- CMMB Health Care
- APM Health Care
- Exchange
- CMMB Nasdaq
- APM Nasdaq
- Market Cap
- CMMB 22.0M
- APM 18.9M
- IPO Year
- CMMB N/A
- APM 2018
- Fundamental
- Price
- CMMB $2.83
- APM $1.96
- Analyst Decision
- CMMB Strong Buy
- APM
- Analyst Count
- CMMB 2
- APM 0
- Target Price
- CMMB $26.50
- APM N/A
- AVG Volume (30 Days)
- CMMB 141.5K
- APM 20.5M
- Earning Date
- CMMB 11-13-2025
- APM 04-30-2025
- Dividend Yield
- CMMB N/A
- APM N/A
- EPS Growth
- CMMB N/A
- APM N/A
- EPS
- CMMB N/A
- APM N/A
- Revenue
- CMMB N/A
- APM N/A
- Revenue This Year
- CMMB N/A
- APM N/A
- Revenue Next Year
- CMMB N/A
- APM N/A
- P/E Ratio
- CMMB N/A
- APM N/A
- Revenue Growth
- CMMB N/A
- APM N/A
- 52 Week Low
- CMMB $2.71
- APM $0.46
- 52 Week High
- CMMB $9.84
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- CMMB 21.60
- APM 52.30
- Support Level
- CMMB $2.96
- APM $1.64
- Resistance Level
- CMMB $3.09
- APM $2.65
- Average True Range (ATR)
- CMMB 0.21
- APM 0.20
- MACD
- CMMB 0.00
- APM -0.04
- Stochastic Oscillator
- CMMB 11.26
- APM 31.68
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.